We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer.
- Authors
Agus, David B; Gordon, Michael S; Taylor, Charles; Natale, Ronald B; Karlan, Beth; Mendelson, David S; Press, Michael F; Allison, David E; Sliwkowski, Mark X; Lieberman, Gracie; Kelsey, Stephen M; Fyfe, Gwen
- Abstract
Pertuzumab, a recombinant humanized monoclonal antibody (2C4), binds to extracellular domain II of the HER-2 receptor and blocks its ability to dimerize with other HER receptors. Pertuzumab represents a new class of targeted therapeutics known as HER dimerization inhibitors. A clinical study was conducted to investigate safety and pharmacokinetics of pertuzumab and to perform a preliminary assessment of HER dimerization inhibition as a treatment strategy.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Vol 23, Issue 11, p2534
- ISSN
0732-183X
- Publication type
Journal Article
- DOI
10.1200/JCO.2005.03.184